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Abstract
High percent mammographic density adjusted for age and body mass index (BMI) is one of the
strongest risk factors for breast cancer. We conducted a meta-analysis of five genome-wide
association studies of percent mammographic density and report an association with rs10995190
in ZNF365 (combined P=9×6·10−10). This finding might partly explain the underlying biology of
the recently discovered association between common variants in ZNF365 and breast cancer risk.
Percent mammographic density reflects the proportion of stromal and epithelial tissues in
relation to fat tissue in the breast. Women with more than 75% dense tissue in the breast are
at a four- to five-fold greater risk of breast cancer than women of the same age and BMI
with little or no dense tissue 1-3. Percent mammographic density has thus been considered
an intermediate phenotype of breast cancer 4-7 and identifying its determinants may provide
novel insights into the etiology of breast cancer.
Lifestyle factors including age, parity, BMI and exogenous hormone levels explain only
20-30% of the between-women variation in percent mammographic density 8. It has been
estimated that 61-67% of the residual variation could be attributable to genetic factors 9 but
linkage and candidate gene association studies have been largely unsuccessful in
reproducibly identifying loci related to mammographic density.
To this end, we conducted a meta-analysis of five genome-wide association studies (GWAS)
of percent mammographic density adjusted for age and BMI within the Marker Of DEnsity
(MODE) consortium: the Nurses' Health Study (NHS) (n=1,590), the Singapore and
Swedish Breast Cancer Study (SASBAC) study (n=1,258), the European Prospective
Investigation Into Cancer and Nutrition - (EPIC-Norfolk) (n=1,142), the Minnesota Breast
Cancer Family study (MBCFS) (n=571) and the TORONTO/MELBOURNE study (n=316).
The total sample size was 4,877 women. All women were of self-described European
descent and the majority (89%) was postmenopausal at the time of mammogram.
Study design, population characteristics and genotyping platforms varied across studies
(Supplementary Tables 1-3). For all studies, percent mammographic density was measured
using the CUMULUS software 10. Genotypes for more than 2 million SNPs were imputed
within each study using Phase II data from HapMap CEU individuals. All studies except
TORONTO/MELBOURNE used linear regression treating percent mammographic density
as a quantitative trait. TORONTO/MELBOURNE selected women in the top and bottom
10% of percent mammographic density and treated women with high density as “cases” and
women with low density as “controls” in a logistic regression model. The differences in
study design (extreme sampling vs. continuous trait) did not allow us to perform meta-
analysis based on the estimated effect size in each study as units of density measurement
were not comparable across studies 11. Instead, a combined test for each SNP was derived
by combining p-values and the direction of association for each study, weighted by the
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square-root of the sample size and the study-specific inflation factor. We calculated an
effective sample size for the TORONTO/MELBOURNE study (n=1,109) to account for
their sampling of women in the tails of the distribution (Supplementary Information).
The quantile-quantile plot and Manhattan plots are depicted in Supplementary Figures 1 and
2. The overall genetic inflation factor was λ=1.033. Although no SNP met the commonly-
used genome-wide significance criterion of P<5×10−8, six SNPs within the same linkage
disequilibrium (LD) block in intron 4 of ZNF365 had p-values <10−6, with the smallest p-
value being observed for rs10995195 for which the ‘C’ allele was associated with lower
mammographic density (P=4.0×10−7, Supplementary Table 4).
A recent GWAS by Turnbull and colleagues, including 3,659 breast cancer cases and 4,897
controls in the first stage and 12,576 cases and 12,223 controls in the second stage, found
that the rs10995190 ‘A’ allele in ZNF365 was associated with decreased breast cancer risk
(OR: 0.86, 95% CI: 0.82-0.91, P=5.1×10−15) 12. The rs10995190 ‘A’ allele is in high LD
with the rs10995195 ‘C’ allele (pair-wise r2 =0.94 in HapMap CEU) and was ranked third in
our meta-analysis of percent mammographic density (P=5.7×10−7; Figure 1).
We attempted to replicate the association between rs10995190 and percent mammographic
density in 1,690 women from the Mayo Clinic Breast Cancer Study (MCBCS) genotyped as
a part of the replication in the breast cancer case-control GWAS by Turnbull colleagues, and
in additional 1,145 women without breast cancer from the Sisters in Breast Screening Study
(SIBS) through in silico replication (Supplementary Information). We found that the ‘A’
allele of rs10995190 was associated with lower percent mammographic density in our
replication studies (P=0.0004), resulting in a combined P-value of 9.6×10−10 (Table 1).
Adjusting for breast cancer case-control status in NHS and MCBCS (P=6.4×10−9) or
excluding breast cancer cases (P=1.1×10−7) did not change the statistical significance of this
association. For two of the three case-control studies (NHS and MCBCS), there was a
significant association between rs10995190 and mammographic density among the controls
(Table 1). Therefore, we find it unlikely that the association between rs10995190 and
mammographic density is driven by confounding due to inclusion of breast cancer cases.
Across studies with genotype data for rs10995190 (not considering studies with imputed
data), the mean change in percent mammographic density per minor allele was −2.01. Based
on this estimate, rs10995190 would explain ~0.5% of the variance in percent
mammographic density.
To assess the extent to which the observed association between rs10995190 and breast
cancer risk might be mediated through mammographic density, we estimated the association
between rs10995190 and breast cancer risk before and after adjustment for mammographic
density using case-control data from NHS, SASBAC and MCBCS (Supplementary Table 5).
From the pooled analysis, including 2,107 breast cancer cases and 2,433 controls, we
observed a significant association between rs10995190 and breast cancer risk, with an effect
size similar to that previously reported (OR: 0.85, 95% CI: 0.76-0.96, P=0.008) 12.
Adjusting for mammographic density slightly attenuated the association (OR: 0.90, 95% CI:
0.80–1.01, P=0.09). These results demonstrate that genetic variation in ZNF365 could
influence breast cancer risk by influencing the proportion of dense tissue in the breast,
although it remains possible that the same locus influences both phenotypes independently.
In addition, we examined if any other known breast cancer SNPs were associated with
mammographic density in our study (Supplementary Table 6). Out of 22 SNPs tested
(excluding rs10995190), two SNPs showed an association with mammographic density;
rs2046210 (ESRI, P=0.005) and rs3817198 (LSP1, P=0.04). Both associations were in the
expected direction as determined by corresponding breast cancer associations. We also
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examined these associations stratified by case-control status, recognizing the lower
statistical power due to the smaller sample size (Supplementary Table 6).
A potential limitation in this study is the inherent measurement error in mammographic
density. In all seven studies, mammographic density was read using the same computer-
assisted thresholding method which has been shown to be highly reproducible with intra-
and inter-reader reproducibility within sites generally greater than 0.9 10. In addition, the
European studies used the medio-lateral oblique (MLO) view, while other studies used the
cranio-caudal (CC) view. Although the percent density measurements from the MLO view
have been shown to be lower than those from the CC view 13,14, both measures are strong
predictors of breast cancer risk. By conducting study-specific GWAS before pooling
summary statistics in a meta-analysis, we minimized the impact of differences in density
measurements across studies.
Mammographic density attenuated the association with breast cancer risk suggesting that the
influence of ZNF365 on breast cancer risk may be mediated in part by mammographic
density. Given that there is measurement error in our phenotype, our ability to demonstrate
mediation through mammographic density is reduced. Nonetheless, these results
demonstrate how an intermediate phenotype can help shed light on the mechanisms
underlying observed SNP-disease associations. The association with rs10995190, while
highly statistically significant, explains only 0.5% of the variance in percent mammographic
density. Further GWAS analyses in larger sample sizes will most likely result in
identification of additional variants.
In summary, we report a novel association between common genetic variation in ZNF365
and percent mammographic density adjusted for age and BMI. The same genetic variant was
recently identified as a breast cancer susceptibility locus suggesting that one or more
variants in the ZNF365 locus acts on breast cancer risk by influencing the proportion of
dense tissue in the breast.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Regional association plot for ZNF365 across a 300kb window. Association of individual
SNPs is plotted as –log10(P) against chromosomal base-pair position. Results of both
genotyped and imputed SNPs are provided. Colors indicate the LD relationship between
rs10995190 and the other markers (red, r2>0.8). The right-hand Y axis shows the
recombination rate estimated from the HapMap CEU population. All p-values are from the
discovery phase.
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